Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Albireo Pharma Inc is a biotechnology business based in the US. Albireo Pharma shares (ALBO) are listed on the NASDAQ and all prices are listed in US Dollars. Albireo Pharma employs 90 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $25.46 |
|---|---|
| 52-week range | $20.30 - $43.41 |
| 50-day moving average | $24.80 |
| 200-day moving average | $29.75 |
| Wall St. target price | $76.80 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-2.50 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $25.46 from 2022-01-21
| 1 week (2022-01-13) | -1.05% |
|---|---|
| 1 month (2021-12-20) | N/A |
| 3 months (2021-10-22) | -12.87% |
| 6 months (2021-07-23) | -17.34% |
| 1 year (2021-01-22) | -27.38% |
|---|---|
| 2 years (2020-01-24) | 9.98% |
| 3 years (2019-01-24) | 10.36% |
| 5 years (2017-01-24) | 37.62% |
| Revenue TTM | $10.8 million |
|---|---|
| Gross profit TTM | $8.3 million |
| Return on assets TTM | -24.89% |
| Return on equity TTM | -24.33% |
| Profit margin | 0% |
| Book value | $9.43 |
| Market capitalisation | $523.2 million |
TTM: trailing 12 months
We're not expecting Albireo Pharma to pay a dividend over the next 12 months.
Albireo Pharma's shares were split on a 1:30 basis on 3 November 2016. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Albireo Pharma shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Albireo Pharma shares which in turn could have impacted Albireo Pharma's share price.
Over the last 12 months, Albireo Pharma's shares have ranged in value from as little as $20.3 up to $43.41. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Albireo Pharma's is 1.4009. This would suggest that Albireo Pharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Albireo Pharma, Inc. , a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis. It has a license agreement with EA Pharma Co. , Ltd. for the development and commercialization of elobixibat.
Walmart files trademarks with the goal to issue its own cryptocurrency and NFTs for use in its digital stores.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.